표적화 리포솜 약물전달 시스템 시장 규모, 점유율, 성장 분석 : 제품별, 기술별, 적응증별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Targeted Liposomes Drug Delivery Market size was valued at USD 1.62 Billion in 2024 and is poised to grow from USD 1.69 Billion in 2025 to USD 2.41 Billion by 2033, growing at a CAGR of 4.5% during the forecast period (2026-2033).

The Targeted Liposomes Drug Delivery Market is witnessing robust growth driven by advancements in drug delivery technologies. These liposomes facilitate precise and controlled release of medications, enhancing therapeutic efficacy while minimizing side effects. The rising prevalence of chronic diseases, combined with a growing demand for personalized medicine, further fuels market expansion. Additionally, continuous research and development initiatives, strategic collaborations, and increased healthcare investments play a pivotal role in market enhancement. North America and Europe dominate the market share, supported by well-established healthcare infrastructures, whereas the Asia-Pacific region presents lucrative opportunities due to rising healthcare advancements and a larger patient demographic. Noteworthy trends include the creation of innovative formulations and the pursuit of targeted therapies, reflecting a dynamic and evolving market landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Targeted Liposomes Drug Delivery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Targeted Liposomes Drug Delivery Market Segments Analysis

Global Targeted Liposomes Drug Delivery Market is segmented by Product, Technology, Indication, End User and region. Based on Product, the market is segmented into Liposomal Paclitaxel, Liposomal Doxorubicin, Liposomal Amphotericin B and Others. Based on Technology, the market is segmented into Stealth Liposome Technology, Non-PEGylated Liposome Technology and DepoFoam Liposome Technology. Based on Indication, the market is segmented into Fungal Diseases, Pain Management, Cancer Therapeutics and Others. Based on End User, the market is segmented into Hospitals, Clinics, Research Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Targeted Liposomes Drug Delivery Market

The increasing interest in personalized and precision medicine has significantly boosted the targeted liposomes drug delivery market. Targeted liposomes serve as innovative delivery systems, providing controlled release of therapeutic agents while minimizing side effects, thereby enhancing overall treatment effectiveness. Additionally, the rising prevalence of chronic conditions, notably cancer, has heightened the demand for advanced drug delivery solutions. As healthcare continues to evolve, targeted liposomes are becoming essential in addressing the complexities of treatment regimens and improving patient outcomes through their ability to deliver drugs more efficiently and effectively to specific sites within the body.

Restraints in the Targeted Liposomes Drug Delivery Market

A key factor hindering the growth of the targeted liposomes drug delivery market is the substantial costs associated with sophisticated liposomal formulations and technologies, which can limit accessibility for many potential users. Additionally, the intricate regulatory landscape and diverse approval processes that vary by region further exacerbate these challenges, potentially postponing the introduction of innovative liposomal products. These financial and regulatory obstacles can complicate market entry for new solutions, restricting the overall advancement of targeted liposome therapies and affecting their availability to patients who could benefit from them.

Market Trends of the Targeted Liposomes Drug Delivery Market

The Targeted Liposomes Drug Delivery market is experiencing significant growth driven by an increasing emphasis on personalized medicine. This trend highlights the customization of liposomal formulations to meet the unique needs of individual patients, thereby enhancing therapeutic efficacy and minimizing side effects. Furthermore, advancements in liposomal technology, including the development of smart and stimuli-responsive liposomes, underscore the industry's commitment to improving the precision of drug delivery systems. As healthcare shifts towards more personalized treatment options, the demand for innovative liposomal formulations continues to rise, positioning this market for sustained expansion and investment in cutting-edge research and development.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Targeted Liposomes Drug Delivery Market Size by Product & CAGR (2026-2033)

• Market Overview
• Liposomal Paclitaxel
• Liposomal Doxorubicin
• Liposomal Amphotericin B
• Others

Global Targeted Liposomes Drug Delivery Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Stealth Liposome Technology
• Non-PEGylated Liposome Technology
• DepoFoam Liposome Technology

Global Targeted Liposomes Drug Delivery Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Fungal Diseases
• Pain Management
• Cancer Therapeutics
• Others

Global Targeted Liposomes Drug Delivery Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Research Laboratories
• Others

Global Targeted Liposomes Drug Delivery Market Size & CAGR (2026-2033)

• North America (Product, Technology, Indication, End User)
  • US
  • Canada
• Europe (Product, Technology, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Technology, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Technology, Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Technology, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacira BioSciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celsion Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acrotech Biopharma, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arbutus Biopharma Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Camurus AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acuitas Therapeutics (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations